GMP approved factory,stable supplying, competitive price
*The following content is generated by AI and is for reference only.
Baloxavir marboxil, often referred to in research contexts by its active moiety or salt form, is a novel antiviral medication developed specifically for the treatment of influenza. The compound functions as a prodrug; upon oral administration, it is rapidly hydrolyzed in the liver and plasma to baloxavir acid, which is the pharmacologically active agent. This active metabolite acts as a selective inhibitor of the cap-dependent endonuclease activity within the influenza virus polymerase complex. By blocking this specific enzymatic function, baloxavir prevents the viral mRNA synthesis required for replication, effectively halting the propagation of the virus early in the infection cycle.
The chemical identity of the prodrug, Baloxavir marboxil, corresponds to the CAS number 1596874-20-8. Its molecular formula is C30H31F3N6O5S. Structurally, it consists of a complex heterocyclic framework designed to optimize bioavailability and tissue distribution, ensuring high concentrations are reached in the respiratory tract where influenza viruses replicate most aggressively. Unlike older neuraminidase inhibitors such as oseltamivir, baloxavir targets a different stage of the viral life cycle, offering a distinct mechanism of action that remains effective against many strains resistant to other drug classes.
Clinically, baloxavir marboxil is indicated for the treatment of acute uncomplicated influenza in patients who have been symptomatic for no more than forty-eight hours. A significant advantage of this therapy is its single-dose regimen, which greatly enhances patient compliance compared to multi-day dosing schedules of competitors. Clinical trials have demonstrated its efficacy in reducing symptom duration by approximately one day when administered promptly after symptom onset. Furthermore, it has shown potent activity in reducing viral load shedding, potentially limiting transmission to others. While generally well-tolerated, common side effects may include diarrhea and bronchitis. As resistance monitoring continues, baloxavir represents a crucial addition to the global arsenal against seasonal and pandemic influenza threats, providing a rapid and effective therapeutic option for high-risk populations.